Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
LONDON - SEED Innovations Ltd (AIM:SEED), an investment company specializing in life sciences and technology ventures, acknowledged the publication of the annual report by its investee company, Little Green Pharma Ltd (LGP), on the ASX. SEED currently holds approximately 2.4% of LGP’s issued share capital, totaling 7,324,796 ordinary shares.
Little Green Pharma, a global medicinal cannabis business, has reported its annual results for the period ending March 31, 2025. The company operates two major production sites, one in Denmark and another in Western Australia, with a combined capacity to produce over 33 tonnes of medicinal cannabis biomass annually.
The Denmark site includes a cultivation facility of 21,500m2 and a 4,000m2 GMP manufacturing facility, while the Western Australian site maintains an indoor cultivation and manufacturing setup. LGP’s products, which adhere to stringent regulations including those of the Danish Medicines Agency and the Therapeutic Goods Administration, are distributed across Australian, European, and other overseas markets.
Focused on patient access and education in the burgeoning global medicinal cannabis market, LGP also engages in clinical research and the development of new delivery systems for its medical-grade cannabis products.
The news comes as part of a Reach announcement, a service used to disseminate non-regulatory news releases to the public, and does not constitute regulatory news required to be disclosed under AIM Rules for Companies or other regulations.
SEED Innovations’ portfolio strategy includes identifying early-stage opportunities with potential investment catalysts and more mature investments offering near-term liquidity. The company’s announcement is based on a press release statement and provides investors with updated information on one of its key holdings.
This acknowledgment of LGP’s annual report publication by SEED Innovations underlines the investment company’s ongoing interest in and support of its portfolio companies, particularly in the high-growth sectors of life sciences and technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.